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A B S T R A C T
In Brazil, cutaneous leishmaniasis is caused predominantly by L. (V.) braziliensis. The few therapeutic drugs
available exhibit several limitations, mainly related to drug toxicity and reduced eﬃcacy in some regions.
Miltefosine (MF), the only oral drug available for leishmaniasis treatment, is not widely available and has not yet
been approved for human use in Brazil. Our group previously reported the existence of diﬀerential susceptibility
among L. (V.) braziliensis clinical isolates. In this work, we further characterized three of these isolates of L. (V.)
braziliensis chosen because they exhibited the lowest and the highest MF half maximal inhibitory concentrations
and were therefore considered less tolerant or more tolerant, respectively. Uptake of MF, and also of phos-
phocholine, were found to be signiﬁcantly diﬀerent in more tolerant parasites compared to the less sensitive
isolate, which raised the hypothesis of diﬀerences in the MF transport complex Miltefosine Transporter (MT)-
Ros3. Although some polymorphisms in those genes were found, they did not correlate with the drug suscept-
ibility phenotype. Drug eﬄux and compartmentalization were similar in the isolates tested, and amphotericin B
susceptibility was retained in MF tolerant parasites, suggesting that increased ﬁtness was also not the basis of
observed diﬀerences. Transcriptomic analysis revealed that Ros3 mRNA levels were upregulated in the sensitive
strain compared to the tolerant ones. Increased mRNA abundance in more tolerant isolates was validated by
quantitative PCR. Our results suggest that diﬀerential gene expression of the MT transporter complex is the basis
of the diﬀerential susceptibility in these unselected, naturally occurring parasites.
1. Introduction
Leishmania (Viannia) braziliensis is the main causative species of
cutaneous leishmaniasis (CL) in Brazil with almost 20,000 new cases
each year (Banuls et al., 2007; Grimaldi et al., 1989; WHO, 2018). In-
fections caused by this species can lead to the destructive mucocuta-
neous manifestation, which is potentially deadly (Burza et al., 2018).
Chemotherapy for leishmaniasis in Brazil relies mainly on the penta-
valent antimonial meglumine antimoniate, a drug with serious
limitations due to toxicity and parenteral administration. Eﬃcacy in CL
treatment with this drug has been reported to be as low as 50% in some
regions of the country (Chrusciak-Talhari et al., 2011; Machado et al.,
2010). The alkylphosphocholine miltefosine (MF) was shown to be
active against Leishmania parasites and is currently the most eﬀective
oral drug for leishmaniasis treatment (Sunyoto et al., 2018). Initial
demonstrations of miltefosine's eﬃcacy for the treatment of visceral
leishmaniasis (VL) in India were followed over time by concerns re-
garding the selection of drug resistant parasites. Resistant clinical
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isolates have already been described (Srivastava et al., 2017). Fur-
thermore, Leishmania susceptibility to miltefosine was shown to vary,
not only between diﬀerent species but also in isolates of the same
species (Bhandari et al., 2012; Espada et al., 2017; Hendrickx et al.,
2015; Kumar et al., 2009; Prajapati et al., 2013; Utaile et al., 2013;
Yardley et al., 2005).
Resistance to MF in Leishmania has been correlated with reduction
in the amount of drug inside the parasite (Deep et al., 2017; Mondelaers
et al., 2016; Perez-Victoria et al., 2003a, 2006a, 2006b; Sanchez-Canete
et al., 2009; Vacchina et al., 2016). The most well accepted hypothesis
for this reduced intracellular drug accumulation is the presence of a
defective complex Miltefosine Transporter (MT)-Ros3, the main
pathway associated with MF transport (Coelho et al., 2014; Fernandez-
Prada et al., 2016; Laﬃtte et al., 2016b; Mondelaers et al., 2016; Perez-
Victoria et al., 2003b, 2006a; Seifert et al., 2007; Shaw et al., 2016).
However, a reduction in MF accumulation and susceptibility has also
been observed in parasites harboring a normal transport machinery,
suggesting that tolerance to the drug could be the result of other me-
chanisms as well (Bhandari et al., 2012; Coelho et al., 2014; Deep et al.,
2017; Obonaga et al., 2014). A recently published review emphasized
the diversity of MF tolerance mechanisms described for Leishmania,
suggesting that this phenotype could be multifactorial (Hefnawy et al.,
2017). For example, MF tolerance has also been attributed to drug ef-
ﬂux (Perez-Victoria et al., 2006b), diﬀerences in membrane interactions
such as variations in phospholipid content (phosphatidylcholine and
phosphatidylethanolamine) of the parasite membrane (Rakotomanga
et al., 2007) and increased detox related proteins (Deep et al., 2017).
In Brazil, MF is not yet approved for use in humans, but two clinical
trials showed superior eﬃcacy in CL treatment when compared with
meglumine antimoniate (Chrusciak-Talhari et al., 2011; Machado et al.,
2010). We have, in a previous study, characterized the susceptibility of
L. (V.) braziliensis clinical isolates recovered from CL patients in Brazil.
The half-maximal eﬀective concentrations (EC50) against these isolates
varied 6-fold and 15-fold for promastigotes and intracellular amasti-
gotes, respectively. Interestingly, these isolates had not been exposed to
miltefosine previously and were recovered from patients before treat-
ment with other leishmanicidal drugs (Espada et al., 2017).
Aiming to identify the molecular basis involved in the variable
tolerance of L. (V.) braziliensis to MF, we chose three isolates from the
same geographical region (Bahia, Brazil) with the least or the highest
drug tolerances, together with the reference strain of this species, to
study drug uptake and compartmentalization and gene expression
proﬁles. Global gene expression analysis revealed diﬀerences that could
explain the diverse phenotypes of susceptibility and uptake.
2. Materials and methods
2.1. Chemical compounds
BODIPY labeled MF [11-(4′,4′-Diﬂuoro-6′-ethyl-1′,3′,5′,7′-tetra-
methyl-4′-bora3′a,4′a-diaza-s¬-indacen-2′-yl)-undecylphosphocholine]
(MT-EtBDP) was prepared as described (Hornillos et al., 2008).
BODIPY-PC [(2-(4,4-Diﬂuoro-5-Methyl-4-Bora-3a,4a-Diaza-s-Indacene-
3-Dodecanoyl)-1-Hexadecanoyl-sn-Glycero-3-Phosphocholine] was
purchased from Molecular Probes®. MitoTracker™ Deep Red FM was
purchased from Invitrogen™ and Lysosomal Staining Reagent - NIR –
Cytopainter from Abcam. Amphotericin B was purchased from Sigma-
Aldrich (St. Louis, MO, USA).
2.2. Parasites
Parasites were grown in M199 medium supplemented with 10%
heat inactivated fetal calf serum (FCS), 0,25% hemin, and 2% male
urine at 25 °C. L. (V.) braziliensis reference strain (MHOM/BR/1975/
M2903) and three clinical isolates previously characterized for sus-
ceptibility to MF by our group (Espada et al., 2017) were used in this
study: MHOM/BR/2005/LTCP16012, which is more sensitive to MF,
and MHOM/BR/2006/LTCP16907 and MHOM/BR/2009/LTCP19446,
which are more tolerant to the drug (Table 1).
2.3. Uptake of labeled phosphocholine and miltefosine
Log-phase promastigotes were incubated in HEPES-NaCl buﬀer
(21mM HEPES, 137mM NaCl, 5 mM KCl, 0,7mM NaH2PO4, 6mM
glucose, pH 7.05) containing 0.3% (w/v) BSA and 500 μM phe-
nylmethylsulfonyl ﬂuoride (PMSF) (Sigma Aldrich) for 15min to inhibit
phospholipid catabolism. Next, 10 μM BODIPY-PC or 1 μM MT-EtBDP
was added and parasites were incubated for 1 h or 5min, respectively,
at 25 °C. In order to remove the non-internalized labeled molecules,
parasites were washed three times with ice-cold HEPES-NaCl con-
taining 0.3% BSA. The parasites were then suspended in PBS for ﬂow
cytometry analyses using Guava EasyCyte Mini Flow Cytometer System
(Millipore) and 20,000 events per sample were evaluated. Statistical
analyses were performed using one-way ANOVA analysis followed by
Tukey's multiple comparison tests in Graph Pad Prism 6.0.
2.4. Confocal microscopy
For MT-EtBDP localization and co-localization assays, 5× 106 log-
phase promastigotes were incubated in the presence of 1.5 μM
MitoTracker™ Deep Red FM or Lysosomal Satining Reagent - NIR for
30min and washed twice with PBS. Parasites were then incubated with
MT-EtBDP in HEPES-NaCl buﬀer supplemented with 0.3% BSA and
500 μM PMSF for 5min and washed three times with HEPES-NaCl
containing 0.3% BSA. Parasites were left to adhere to culture plates
previously treated with 0.5% poly-lysine for approximately 1min.
Confocal images were captured in a 1024× 1024 pixel format using a
Zeiss LSM 780 confocal laser scanning inverted microscope (Carl Zeiss,
Germany). Images were captured with an alpha Plan-Apochromatic
100x/1.46 Oil DIC M27 objective (Zeiss), applying a zoom factor of 2.
Alternatively, for incorporation assays, 5× 106 log-phase promas-
tigotes were left to adhere to CELLView™ (Greiner bio-one) culture
dishes previously treated with 0.1% poly-lysine for approximately
1min. Non-adhered parasites were removed, and 100 μL of 1mg/mL
PBS-glucose was added. After focusing, video acquisition was started
and MT-EtBPD was added to a ﬁnal concentration of 0.5 μM. Time-
series images were acquired in a 512×512 pixel format with an image
interval of 970ms for 7min and 39 s. Image quantiﬁcation was per-
formed using the ROI tool in the Zen 2011 software (Zeiss, version
11.00.190) and processing with FIJI software (Schindelin et al., 2012).
Fluorescence intensity was calculated for each parasite present on focal
Table 1
Susceptibility of promastigotes and intracellular amastigotes of L. (V.) brazi-
liensis isolates to miltefosine.
Miltefosinea Amphotericin B
Promastigotesb Amastigotesc Promastigotesb
EC50 (μM)d EC50 (μM)d EC50 (nM)d
MHOM/BR/1975/M2903 53.5 ± 6.6 2.7 ± 0.2 45.8 ± 1.4
MHOM/BR/2005/LTCP16012 22.9 ± 3.7 0.8 ± 0.1 50.9 ± 3.0
MHOM/BR/2006/LTCP
16907
101.2 ± 6.0 3.3 ± 0.4 39.7 ± 0.5
MHOM/BR/2009/LTCP
19446
90.4 ± 5.2 4.2 ± 0.2 27.5 ± 1.6
a Data previously described in Espada et al. (2017).
b Activity of miltefosine or amphotericin B determined against late log phase
promastigotes, through MTT conversion.
c Amastigote assays performed in infected BMDM.
d Eﬀective concentrations (EC50 and EC90). Mean ± standard deviation of
three independent experiments performed in triplicates.
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ﬁeld and background ﬂuorescence intensity was used as control. Area
under the curve calculation followed by t-test analysis were performed
using GraphPad Prism 6.0.
2.5. Measurement of residual MF at diﬀerent time points
Log-phase promastigotes were incubated with 1 μM MF-EtBPD in
HEPES-NaCl buﬀer supplemented with 0.3% BSA and 500 μM PMSF for
5min. Parasites were washed with HEPES-NaCl 0.3% BSA and 5×106
parasites were ressuspended in 1mg/mL PBS-Glucose for MT-EtBDP
uptake quantiﬁcation. After 1, 2, 24 and 48 h, 5× 106 parasites were
pelleted and the supernatant was recovered. Parasites were washed
again with HEPES-NaCl 0.3% BSA to remove non-internalized mole-
cules and the amount of residual ﬂuorescence inside the parasites was
evaluated by ﬂow cytometry using Guava EasyCyte Mini Flow
Cytometer System. A total of 20,000 events were analyzed. Results were
expressed as the ﬂuorescence remaining inside the parasite compared to
the initial ﬂuorescence after the initial uptake.
Alternatively, for labeled MF eﬄux determination, the ﬂuorescence
in the recovered supernatant was measured using POLARstar® Omega
microplate reader with excitation at 485 nm and emission at 530-
10 nm.
2.6. DNA sequencing and analyses
Total genomic DNA was isolated using DNAzol reagent
(Invitrogen™). Speciﬁc primers for each gene analyzed in this study
(Table S1) were used for ampliﬁcation with Accuprime Taq DNA
polymerase system (Invitrogen™) or Platinum® Taq DNA Polymerase
High Fidelity (Invitrogen™). Internal and external primers were de-
signed using Primer 3 Software (Koressaar and Remm, 2007; Rozen and
Skaletsky, 2000) (Table S1) based on the sequences of MT
(LbrM.13.1380 and LbrM.13.1400) and Ros3 (LbrM.32.0580) L. (V.)
braziliensis M2904 genes available at TriTrypDB (http://trytripdb.org)
(Aslett et al., 2010). For MT genes, each ORF was ampliﬁed separately
using the primer pair LbrM.13.1380 ORF-F and LbrM.13.1380 ORF-R
for the LbrM.13.1380 gene and the pair LbrM.13.1400 ORF-F and
LbrM.13.1400 ORF-R for the LbrM.13.1400 gene. Ampliﬁed products
containing these ORFs were then used as template for further ampliﬁ-
cation of smaller fragments. For this purpose, an external primer spe-
ciﬁc for each gene, and an internal primer in common for both genes
were used. The ampliﬁcation with the primer pair LbrM.13.1380 ORF-F
(or LbrM.13.1400 ORF-F) and R3 resulted in a 2.4 kb fragment of MT,
which has an intersection region with the fragment ampliﬁed with
LbrM.13.1380 ORF-R (or LbrM.13.1400 ORF-R) and F3 primer pair
(1.2 kb fragment). PCR ampliﬁed products of each fragment were
puriﬁed using PureLink® Quick Gel Extraction kit (Invitrogen™) and
then each fragment was individually cloned in the pGEM®-T Easy
Vector system (Promega).
Nucleotide sequences were determined with Big Dye Terminator
v3.1 Cycle Sequencing kit (Applied Biosystems). Several primers an-
nealing to sequences inside (R1, F1, R2, F2, R3, F5) and outside (M13-F,
M13-R, LbrM.13.1380 ORF-F/LbrM.13.1400 ORF-F and LbrM.13.1380
ORF-R/LbrM.13.1400 ORF-R) the cloned inserts were used in order to
improve sequencing quality (Table S1).
For Ros3 gene sequencing, the ORF (1092 bp) was directly cloned.
Thus, Ros3 was ampliﬁed using the primer pair LbrM.32.0580 ORF-F
and LbrM.32.0580 ORF-R (Table S1), cloned in pGEM®-T Easy Vector
system and sequenced as described. At least 4 individual clones of each
clinical isolate were sequenced for each gene.
Single nucleotide polymorphisms (SNPs) analyses were performed
using novoSNP (Weckx et al., 2005) and visual inspection. For analyses
performed using novoSNP, a score of 20 was chosen as a cutoﬀ. In case
of heterozygosis, only polymorphisms present in two or more clones, or
in one clone and in the reference strain were validated. For visual in-
spection, a consensus sequence of each clone of each isolate and
reference strain was obtained using Seqman (DNASTAR). These se-
quences were aligned using MegAlign (DNASTAR) and polymorphisms
between sequences were annotated. Again, in case of heterozygosis only
polymorphisms present in two or more clones, or in one clone and in
the reference strain were validated. In order to obtain a consensus se-
quence for each isolate, consensus of clones were aligned and nucleo-
tide sequences are available at GenBank under submission IDs:
2166810, 2166809 and 2166797.
2.7. Susceptibility of clinical isolates to amphotericin B (ampB)
The activity of ampB against promastigotes of L. (V.) braziliensis
isolates and reference strains was assessed by the MTT assay (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) as previously
described (Zauli-Nascimento et al., 2010). Brieﬂy, 2×106 log-phase
promastigotes were incubated in presence of increasing concentrations
of ampB (0–700 nM). After 24 h, cell viability was determined by in-
cubation with MTT followed by optical density (OD) absorbance at
595 nm (referenced at 690 nm). EC50 values were calculated by sig-
moidal regression curves using GraphPad Prism 6.0 software.
2.8. RNA preparation
Total RNA from log-phase promastigotes was obtained using
RNEasy® mini kit (Quiagen®) following manufacturer speciﬁcations.
Alternatively, RNAs were extracted with Trizol® according to the
manufacturer's instructions and then were puriﬁed using the RNEasy
mini kit in order to improve RNA purity. RNA samples were then
treated with DNAse I Ampliﬁcation Grade (Invitrogen™) for DNA con-
tamination removal according to manufacturer's instructions.
2.9. RNA sequencing and data analysis
cDNA library preparation and sequencing were performed at
Oklahoma Medical Research Foundation NGS Core (Oklahoma, USA).
RNA integrity was determined using the Agilent TapeStation 4200
system and Poly(A) enriched stranded cDNA libraries were obtained
using Illumina TruSeq Sample Preparation kit (San Diego, CA, USA).
Pair-end sequencing (2×150bp) was performed on the Illumina HiSeq
3000 platform.
FastQC software was used to evaluate library sequence quality
(Andrews, 2010). Illumina adapter removal and trimming was done
using the Cutadapt tool in pair-end mode (Martin, 2011). Reads were
trimmed for removal of bases with average phred score under 20, and
also for reads with less than 20 bases. Bowtie 2 (version 2.3.4)
(Langmead and Salzberg, 2012) was used to map sequences against the
TriTrypDB L. (V.) braziliensis M2904 genome (release 35). Two mis-
matches per read were allowed. Aligned libraries were sorted using
Samtools (Li et al., 2009). Featurecounts program was then used to
determine the number of mapped reads over each CDS coordinate on
reference genome (Liao et al., 2014).
Diﬀerential gene expression was assessed using Limma R package
(Bioconductor) (Ritchie et al., 2015). The analysis protocol was based
on a previous study (Law et al., 2016). Brieﬂy, count tables were loaded
on RStudio and transformed to counts per million (CPM). Features
harboring CPM values under 1 were ﬁltered out of the analysis. A
Multidimensional Scaling (MDS) plot was then generated in order to
evaluate the replicate weight for further diﬀerential gene expression
analysis. TMM (trimmed means of M-value) and voom normalization
methods were then applied in order to minimize biases caused by
highly expressed genes (heteroscedascity). P-value was adjusted by the
Benjamini and Hocherg method (Benjamini and Hochberg, 1995) and
genes were considered diﬀerentially expressed between isolates when
presenting fold-change values above 2 and p-value under 0.05. Com-
parisons between diﬀerentially expressed genes (DEG) in sensitive and
tolerant strains and in the reference strain M2903 were identiﬁed by the
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analysis of diﬀerent pairs (LTCP16012 vs LTCP16907, LTCP16012 vs
LTCP19446, LTCP16012 vs M2903). A Venn Diagram was produced
indicating the number of genes in each area of intersection (Fig. 5).
2.10. Real time PCR (RT-PCR)
Ros3 diﬀerential expression found among the isolates by RNAseq
was validated by real-time RT-PCR (qPCR) of this region. RNA used as
template for cDNA synthesis was the same RNA used for transcriptome
sequencing. Generation of cDNA molecules from RNA was done using
MuLV Reverse Transcriptase (Applied Biosystems). Brieﬂy, 6 μg of
DNAse treated RNA were incubated with 1 μg Random Primers
(Invitrogen™) for 10min at 4 °C. After this period 5X MulV-RT buﬀer,
0.1 M DTT, 25mM MgCl2 and 10 mM dNTPs were added to the system
and incubated at 42 °C for 2 min. Reverse Transcriptase was then added
to the RT + tubes but not the RT-tubes (control of DNA absence). The
reaction was incubated at 25 °C for 10 min, followed by incubation at
48 °C for 30 min and 95 °C for 5 min according to the manufacturer's
instructions.
One hundred nanograms of in vitro synthesized cDNA was used as
template. qPCR was performed in a StepOne™ Plus System (Applied
Bios ystems) using SYBR® Green PCR Master Mix (Thermo Fisher
Scientiﬁc, Waltham, MA, USA). The following program was used: 95 °C
for 10min followed by 40 cycles at 95 °C for 15s, 60 °C for 60s, and
72 °C for 20s. Primers used to amplify the target and reference genes
were designed using Primer3 (Koressaar and Remm, 2007; Rozen and
Skaletsky, 2000) and manufactured by IDT (Integrated DNA Technol-
ogies, Inc.). A 148 bp fragment of Ros3 gene was ampliﬁed using the
primer pair Ros3-F and Ros3-R (Table S1). The housekeeping GAPDH
gene was used for normalization and was ampliﬁed using the primer
pair GAPDH-F and GAPDH-R, which ampliﬁes a 147 bp GAPDH gene
fragment (Table S1).
Three biological replicates for each isolate, and three technical re-
plicates of each sample were evaluated for Ros3 and GAPDH mRNA
abundance determination. The threshold cycle (Ct) obtained for Ros3 in
each sample was normalized by the Ct of the GAPDH gene (reference
gene). The 2−ΔΔCt equation was used to determine the relative ex-
pression of Ros3 genes in these isolates compared to the reference strain
M2903 (Livak and Schmittgen, 2001). 2−ΔΔCt values were then plotted
on GraphPad prism 6 and statistical analysis performed using one-way
ANOVA analysis followed by Tukey's multiple comparison tests.
3. Results
3.1. Susceptibility of L.(V.) braziliensis clinical isolates to ampB
Aiming to understand if the intrinsic variation of susceptibility to
MF observed was exclusive to this drug or a more widespread phe-
nomenon, we evaluated the susceptibility of the clinical isolates used in
this study to ampB. Although some degree of variability was found the
diﬀerences between the isolates’ ampB EC50 were much less pro-
nounced than the 6-fold variations found for MF, varying from 27 to
46 nM. Furthermore, the susceptibility phenotype was inversely corre-
lated (r=−0.80 p=0.33) for these two drugs: LTCP 16012, the most
sensitive isolate for MF, was the least sensitive for ampB, and inversely,
LTCP 16907 and LTCP 19446 were more susceptible to ampB (Table 1).
3.2. Uptake of MF inversely correlates to MF susceptibility
The amount of MF accumulated inside the parasite was previously
shown to be strictly related to parasite sensitivity to MF, regardless of
the Leishmania species and the origin of tolerance to MF (intrinsic or
acquired) (Coelho et al., 2014; Deep et al., 2017; Fernandez-Prada
et al., 2016; Mondelaers et al., 2016; Perez-Victoria et al., 2003a,
2006a).
To evaluate whether MF accumulation diﬀered in these isolates, we
quantiﬁed the uptake of a BODIPY-labeled MF (MT-EtBDP) by ﬂow
cytometry in one sensitive (LTCP 16012), two tolerant isolates (LTCP
16907 and LTCP, 19446) and for the reference strain M2903. As MT is a
P4-ATPase involved in phospholipid transport in Leishmania parasites
(Perez-Victoria et al., 2003b), and MF (hexadecilphosphocholine) is a
phosphocholine analogue, we also determined whether BODIPY-PC
uptake was impaired in less sensitive isolates.
All clinical isolates and the reference strain revealed diﬀerences in
MT-EtBDP uptake when compared to each other (Fig. 1). For BODIPY-
PC, diﬀerential uptake was also observed for all clinical isolates. The
uptake of BODIPY-PC by the reference strain was not signiﬁcantly dif-
ferent from LTCP 16012 and LTCP 16907 (Fig. 1). The amount of MT-
EtBDP and BODIPY-PC accumulated inside the parasite was inversely
correlated with MF susceptibility (r=−0.80, p=0.33 and r=−0.70,
p=0.23, respectively) so that LTCP 16012 (EC50= 22.9 μM) retained
both more BODIPY-PC and MT-EtBDP and LTPC 16907
(EC50= 101.2 μM) and LTCP 19446 (EC50= 90.4 μM) retained less of
these labeled molecules (Fig. 1).
Diﬀerential uptake of MT-EtBDP was also observed by confocal
microscopy. MT-EtBDP was added to parasites and the incorporation of
labeled miltefosine was followed during eight minutes. Fluorescence
intensity inside each parasite on the focal ﬁeld over time was then
measured resulting in a MT-EtBDP uptake curve. As previously ob-
served, LTCP 19446 accumulated less MF in all time points evaluated
compared to LTCP 16012 (Fig. 2). Area under the curve analyses fol-
lowed by T test showed signiﬁcant diﬀerences in the amount of in-
tracellular MF and uptake kinetics so that the LTCP 19446 isolate ac-
cumulated MF slower and in lower amounts compared to LTCP 16012.
Background ﬂuorescence intensity was also measured and did not in-
crease over time (Fig. 2).
3.3. Measurement of residual intracellular MF at diﬀerent time points
The eﬄux of MF has also been pointed out as a possible mechanism
of resistance in Leishmania parasites (Perez-Victoria et al., 2006b). In
Fig. 1. Uptake of labeled phosphocholine MT-EtBDP (A) and PC-BODIPY (B) by
L. (V.) braziliensis isolates and the reference strain M2903. Isolates were in-
cubated with labeled molecules and ﬂuorescence intensity inside parasite was
measured by ﬂow cytometry. Results are representative of three independent
experiments and show the mean and standard deviation of ﬂuorescence mea-
sured for three technical replicates.
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order to evaluate MF remaining inside parasites after internalization,
parasites were loaded with MT-EtBDP and successive measurements of
ﬂuorescence retained in the cell bodies were done by ﬂow cytometry at
1 h, 2 h, 24 h and 48 h for LTCP 16012 and LTCP 19446 isolates (Fig. 3).
At point 0 h, just after uptake, the isolates demonstrated the diﬀerential
uptake of MF described above. During the follow-up, no signiﬁcant
diﬀerences in MF retention were observed. After 48 h, both isolates
presented a 25% reduction in MT-EtBDP ﬂuorescence compared to the
intracellular drug detected at time 0, suggesting that not the eﬄux but
the diﬀerential intake might be the reason for the diﬀerential suscept-
ibility to MF (Fig. 3). Fluorescence in the culture supernatant was not
detected. These data suggested that the drug metabolism was similar
among these isolates.
3.4. Intracellular MF localization in L.(V.) braziliensis clinical isolates
In order to evaluate if diﬀerential susceptibility could be a result of
MF storage in diﬀerent cell compartments in more and less sensitive
isolates, MF localization inside these parasites was evaluated (Fig. 4).
MT-EtBDP location was similar in both isolates (LTCP 16012 and LTCP
19446), being concentrated mainly in the anterior portion of the
parasites' cell body. The labeling pattern, close to the ﬂagellum and
kinetoplast, and lateral to the nucleus suggested that MF could be re-
tained in organelles such as the mitochondrion and multi-vesicular
tubule. Labeling parasites simultaneously with Mitotracker and MT-
EtBDP revealed a partial co-localization of these two ﬂuorescent-la-
beled molecules, suggesting that MF partially localized to the mi-
tochondrion (Fig. 4A). On the other hand, simultaneous labeling with
Lysonir (marker for acidic compartments) and MT-EtBPD did not in-
dicate a co-localization, suggesting that MF do not accumulate in the
parasite's multi-vesicular tube (Fig. 4B).
Fig. 2. Labeled miltefosine (MT-EtBDP) uptake evaluated by confocal micro-
scopy. Parasites were adhered to poly-lysine coated plates and MF was added.
Uptake was monitored during 8min and ﬂuorescence intensity over time was
calculated. Uptake of MT-EtBDP (green) by L. (V.) braziliensis isolates LTCP
16012 (A) and LTCP 19446 (B) at the time of MT-EtBDP addition and after 3:30
and 7:39min. The complete video is available as a supplementary ﬁle. (C)
Measured ﬂuorescence of each parasite in the focal ﬁeld was plotted for area
under the curve (AUC) analysis. Black lines represent the mean and gray shade
represents the standard deviation of ﬂuorescence intensity measured for each
isolate population (LTCP 16012 n=17 and LTCP, 19446 n=11). Small dotted
line represents the mean and SD of ﬂuorescence units measured for background
in diﬀerent regions of the plate.
Fig. 3. Residual ﬂuorescence inside L. braziliensis isolates LTCP 16012 and
LTCP 19446 was assessed by ﬂow cytometry. After initial uptake determination,
ﬂuorescence associated with cell bodies was measured after 1 h, 2 h, 24 h and
48 h. Fluorescence intensity at each point time was normalized by the initial
uptake of MT-EtBDP since these isolates showed diﬀerences in drug uptake.
Each point represents mean and SD of three technical replicates and the graph
show a representative experiment of three.
Fig. 4. Localization of MT-EtBDP in L. braziliensis promastigotes was analyzed
by confocal microscopy. For both isolates, the same pattern of MT-EtBDP la-
beling (green) was observed (A and B) being mostly concentrated in the ante-
rior portion of parasite, near the ﬂagellar pocket and around nucleus. For co-
localization assays, parasites were initially labeled with Hoechst (blue), (A)
Mitotracker Deep Red FM (red) or (B) Lysonyr (red). After incubation with MT-
EtBDP co-localization was determined by overlapping images obtained for each
labeling.
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3.5. Nucleotide sequencing of the genes encoding the MT-Ros3 complex
Since the diﬀerential MF susceptibility found in these L. (V.) bra-
ziliensis clinical isolates was shown to be correlated to diﬀerential drug
uptake, we characterized the genes encoding the MF transporter. In L.
(V.) braziliensis, an extra copy of the MT gene (LbrM13.1380) is present
(LbrM.13.1400). These two copies exhibit 99% nucleotide identity. Both
copies of the MT and the Ros3 genes were sequenced. We found poly-
morphisms between the M2903 sequence obtained and data available
for the M2904 type strain (http://tritrypdb.org/tritrypdb/) as well as
polymorphisms between the isolates (Table S2). Analyses of
LbrM.13.1380, the orthologue of L. (L.) donovani MT revealed 32
polymorphisms among the analyzed sequences, of which 9 were sy-
nonymous and 23 non-synonymous substitutions (Table S2). A similar
number of polymorphisms was observed for the paralogue of this gene
(LbrM.13.1400), with substitutions of which 13 were synonymous and
26 non-synonymous (Table S2). Despite the high number of non-sy-
nonymous polymorphisms found between the sequences, none of them
could justify the diﬀerential susceptibility and uptake of MF found in
these clinical isolates, since these variations were found simultaneously
in a less susceptible isolate and a more susceptible or reference strains,
or were not present in both less susceptible clinical isolates at the same
time.
As an eﬃcient MF transport in Leishmania depends not only on MT
but also on the Ros3 protein (Perez-Victoria et al., 2006a), we also
determined the nucleotide sequence of the LbrM.32.0580 gene. The
analysis revealed 6 polymorphisms between the sequences of the three
isolates, and of the M2903 and M2904 reference strains, of which 3
were synonymous and 3 were non-synonymous substitutions (Table
S2). None of the variations observed could be correlated with the dif-
ferent phenotypes of MF susceptibility and uptake.
3.6. Transcriptome analysis reveals DEG between sensitive and tolerant
isolates
In order to identify potential genes involved in the diﬀerential
phenotype of susceptibility to MF, whole transcriptome was performed
in log-phase promastigotes of sensitive and tolerant isolates.
After library trimming, reads were mapped to the M2904 sequence
and all samples presented alignment rates above 94%. The number of
reads aligning to each feature was counted and 65 genes out of the 8176
annotated were ﬁltered out for having CPM<1. Normalized libraries
were then analyzed for diﬀerential gene expression discovery. Only
DEG presenting fold change above 2 and p-value under 0.05 were
considered. Within these conditions, the greatest number of DEG was
found for the comparison between LTCP 16907 and the reference strain
M2903 followed by the comparison between LTCP 16012 and LTCP
16907, which presented 432 and 369 DEG events, respectively (Table
S3). On the other hand, the least number of DEG was found in the
comparison between LTCP 16012 and the reference strain M2903 with
151 genes diﬀerentially expressed. The number of DEG revealed in the
other comparisons is described in Table S3. The complete data set
listing the DEGs found in all pairwise comparisons is presented in
Tables S4–S9.
A Venn diagram was generated with the comparisons between the
more tolerant isolate LTCP 16012 with all the others. The aim was to
identify the cluster diﬀerentially expressed when LTCP 16012 was
compared with both LTCP 16907 and LTCP 19446 (less tolerant) but
not with the type strain M2903 (Fig. 5, Table S10). We found 36 DEG
clustering between sensitive and tolerant isolates. Except for three
genes, the majority of DEG identiﬁed were in accordance between the
comparisons, being up or downregulated in both tolerant isolates when
compared to sensitive isolates (Fig. 5).
Interestingly, Ros3 mRNA was found upregulated in the sensitive
Fig. 5. RNAseq revealed genes diﬀerentially
expressed in both tolerant isolates compared to
the sensitive strain, but absent in comparisons
with M2903. Those genes were selected as pos-
sibly related to MF tolerance in these L. (V.)
braziliensis clinical isolates. The table lists the
description of these 36 DEG genes. Genes
marked in green are upregulated in the sensitive
isolate (LTCP 16012) compared to both tolerant
strains (LTCP 16907 and LTCP, 19446). Genes in
red are downregulated in the sensitive strain
compared to tolerant strains. Genes shown in
gray were found to be diﬀerentially expressed in
these contrasts but not in the same direction,
being upregulated in one comparison but down
in the other. The detailed list of these 36 DEG
containing logFC and p-value information is
available as Supplementary Table 4.
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isolate compared to the tolerant isolates. When we compared LTCP
16012 with both LTCP 16907 and LTCP 19446, Ros3 appeared 2.05 and
2.14-fold upregulated in the sensitive isolate when compared to LTCP
16907 and LTCP 19446 tolerant isolates, respectively.
The other 35 DEG (Table S10) observed in this cluster are under
investigation for genes potentially related to MF susceptibility and
uptake in these isolates.
3.7. Validation of Ros3 as a potential gene involved in MF susceptibility
In order to validate Ros3 diﬀerential expression we quantiﬁed Ros3
mRNA by qPCR. The housekeeping GAPDH gene was used for nor-
malization purposes. Relative expression of Ros3 mRNA was de-
termined adopting M2903 strain as a reference. Data obtained for LTCP
16907 did not show clear diﬀerences in reference to the type strain
M2903, due to sample heterogeneity. However, the proﬁle of Ros3
expression observed in RNAseq experiments was conﬁrmed using the
qPCR approach. Ros3 mRNA abundance was higher in LTCP 16012
compared to M2903 and LTCP 16907 (approximately 2-fold). The
comparison between LTCP 16012 and LTCP19446 revealed a more
pronounced diﬀerence with an approximately 4-fold increase in the
more sensitive isolate (Fig. 6).
4. Discussion
In this work, we investigated whether the mechanisms previously
described as responsible for MF resistance were involved in the diﬀer-
ential susceptibility to this drug observed amongst L. (V.) braziliensis
clinical isolates. For this purpose, three L. (V.) braziliensis isolates were
chosen based on their geographical origin and polar tolerance to mil-
tefosine (the highest and the lowest from Bahia state in a panel of 17
previously characterized isolates). One more sensitive (LTCP 16012),
two more tolerant (LTCP 1607 and LTCP, 19446) isolates and a re-
ference strain for this species were used.
The uptake of labeled MF (MT-EtBDP) and phosphocholine (PC-
BODIPY) were evaluated in these parasites by two diﬀerent meth-
odologies. Flow cytometry results showed that both, MT-EtBDP and PC-
BODIPY were diﬀerentially accumulated by sensitive and tolerant
parasites and this uptake was inversely correlated to MF susceptibility.
The kinetics of drug entry in the isolates LTCP 16012 and LTCP 19946
led to a slower and less pronounced accumulation. Therefore, MF in-
ternalization and retention inside the parasite was strictly correlated to
MF susceptibility. Similar results were previously described for
Peruvian L. (V.) braziliensis isolates (Sanchez-Canete et al., 2009),
which presented 4-fold diﬀerences in internalization rates, despite the
less striking diﬀerence in susceptibility observed (EC50 for promasti-
gotes varying between 80 and 140 μM) (Sanchez-Canete et al., 2009).
Diﬀerences in MF internalization causing susceptibility variation were
also observed in other Leishmania species such as L. (L.) donovani (Deep
et al., 2017) and L. (L.) infantum (Fernandez-Prada et al., 2016; Laﬃtte
et al., 2016a; Mondelaers et al., 2016).
Since the MT-Ros3 complex is responsible for the inward transport
of phospholipids in Leishmania, the ﬁnding that PC internalization was
also reduced in tolerant isolates suggested that the intrinsic diﬀerences
in these parasites could be related to this complex. Variation in PC
uptake was also observed in L. (L.) amazonensis selected by MF drug
pressure (Coelho et al., 2014). Together, our ﬁndings showed an in-
trinsic diﬀerence in MF susceptibility among these isolates (since they
were never exposed to MF) that was correlated to the amount of MF
these parasites were able to internalize. Additionally, the diﬀerences in
PC internalization suggested that the mechanism involved in these
phenotypes was responsible for both, PC and MF transport in L. (V.)
braziliensis.
It has already been shown that impairment of the MT-Ros3 complex
causes alterations in membrane composition and symmetry (Fernandez-
Prada et al., 2016; Weingartner et al., 2010). Moreover, change in
membrane phospholipid composition was observed in Leishmania
parasites after treatment with MF, with an increase in phosphatidy-
lethanolamine and reduction in phosphatidylcholine levels due to a
reduction in choline uptake (Rakotomanga et al., 2007). All these
ﬁndings led us to consider the MT-Ros3 complex as the cause of the
diﬀerences in susceptibility and uptake of MF.
MF resistance has been strongly correlated with MT and/or Ros3
gene mutations, causing signiﬁcant reduction in MF transport and thus
increasing the tolerance of the parasite to this drug (Coelho et al., 2014;
Fernandez-Prada et al., 2016; Laﬃtte et al., 2016a; Mondelaers et al.,
2016; Perez-Victoria et al., 2003b; Seifert et al., 2007; Shaw et al.,
2016). Mutations in genes encoding this complex have even been re-
lated to a reduction in sensitivity to another leishmanicidal drug, ampB,
due to changes in membrane lipid composition (Fernandez-Prada et al.,
2016). The determination ofMT-Ros3 coding sequences in these isolates
revealed a number of polymorphisms in the MT genes but without a
pattern that could be assigned to more tolerant or sensitive isolates.
Moreover, the classical hotspots related to MF resistance caused by MT
mutations in other Leishmania species were not observed in these iso-
lates (Bhandari et al., 2012; Coelho et al., 2012; Cojean et al., 2012;
Mondelaers et al., 2016; Perez-Victoria et al., 2003a). Therefore, we
were not able to correlate diﬀerences in susceptibility and uptake to the
polymorphisms found among these isolates.
The diﬀerences in susceptibility in these isolates could be also re-
lated to an increased ﬁtness of tolerant parasites as described as a MF
resistance mechanism in L. (L.) donovani (Deep et al., 2017). Such
changes would be apparent when parasites were submitted to other
challenges and that was tested determining ampB activity against these
isolates. A small degree of variability was observed in the susceptibility
to ampB in these isolates but without signiﬁcance or correlation with
the diﬀerences in MF susceptibility. Similar ﬁndings were described by
Mondelaers et al. (2018) on MF resistant L. infantum selected in vitro
and/or recovered from patients that retained ampB susceptibility.
Drug eﬄux is a well-known drug-resistance mechanism in
Leishmania described mainly in association with pentavalent anti-
monials (Hefnawy et al., 2017) but that has also been correlated with
MF resistance (Perez-Victoria et al., 2006b). The analysis of ﬂuores-
cence decay in parasites loaded with MF indicated that both sensitive
and tolerant isolates presented the same reduction in ﬂuorescence units,
suggesting that eﬄux was not diﬀerent in these parasites. It should be
stressed that, as we were not able to measure MF externalized from the
parasite, we cannot ensure whether the reduction in MF inside the
parasite over time was a result of eﬄux or of drug metabolism.
Nevertheless, the decay in MF resulting from eﬄux and/or drug
Fig. 6. Relative abundance of Ros3 mRNA normalized by GAPDH mRNA ex-
pression for each L. (V.) braziliensis isolate compared to M2903. mRNA quan-
tiﬁcation was assessed by qRT-PCR and normalized using the 2ΔΔCt method.
Three biological replicates of each isolate were evaluated in three technical
replicates of each sample.
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metabolism does not seem to be the cause of the diﬀerential suscept-
ibility in these isolates.
Confocal microscopy of MT-EtBDP labeled LTCP 16012 and LTCP
19446 isolates revealed that MF localizes partially to the mitochon-
drion. In addition, the MF localization did not diﬀer among these iso-
lates. MF partial co-localization with the mitochondrion is an expected
ﬁnding since the mechanism of MF's action involves cytochrome C
oxidase inhibition resulting in mitochondrial depolarization (Luque-
Ortega and Rivas, 2007; Santa-Rita et al., 2004).
The analysis of the transcriptome of the study isolates was then
employed as a tool to identify the reasons accounting for the unequi-
vocal diﬀerences in drug accumulation observed. Among the DEG
found in the comparisons of tolerant and sensitive parasites, Ros3 stood
out. The Ros3 gene encodes the beta-subunit of the MF-Ros3 complex,
and although a higher abundance of Ros3-mRNA was found in the more
sensitive strain, the same was not observed for MT transcripts. This is
somewhat surprising since the complex seems to act as a whole with
mutually dependent components. However, similar results were ob-
served by Sanchez-Canete et al. (2009) in L. (V.) braziliensis Peruvian
isolates, in which Ros3 was shown to act as a limiting factor in L. (V.)
braziliensis MT-Ros3 transport rate. Ros3 gene overexpression was en-
ough to increase both, MT and Ros3 levels in the parasite membrane
(Sanchez-Canete et al., 2009) and could explain why MT transcripts
were not found upregulated in these isolates.
This study was inspired by the urgency in making available new
agents for the treatment of Brazilian tegumentary leishmaniasis caused
by L. (V.) braziliensis. Two clinical trials conducted in Brazil found
approximately 70% cure rates in CL patients treated with MF. It is not
yet known if parasite susceptibility was a playing factor in failure and
that will be an important investigation to be pursued. Further studies
are necessary in order to evaluate whether or not these diﬀerences in in
vitro susceptibility reﬂect diﬀerent cure rates. Furthermore, our results
again point to the need of new molecules for Leishmania parasites and
molecule modiﬁcations in MF in order to overcome the MT-Ros3
complex essentiality for MF entrance in Leishmania parasites. We should
however stress that one of the limitations of this study is that only three
natural isolates were evaluated, and from only one region in Brazil.
There is therefore a clear need for a functional evaluation of the
pathways studied here in a larger number of isolates.
In conclusion, reduced MF susceptibility in Brazilian L. (V.) brazi-
liensis was found to be related to decreased drug accumulation.
Decreased transport seems to be caused by reduced Ros3 mRNA ex-
pression rather than polymorphisms in MT-Ros3 complex coding genes.
The data described here illustrates the need for parasite susceptibility
studies as a recommendation before drug implementation. New mole-
cules and modiﬁcations in MF that could overcome MT-Ros3 depen-
dence are highly encouraged by our ﬁndings.
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